Needleye Robotics provides biopsy and needle-based therapy through AI-powered robotics. In Europe, around 1 million prostate biopsies are carried out each year. Biopsy is still affected by diagnostic errors between 30% and 50%. The main sources of error are target detection and needle insertion: both operator dependent! We aim to radically improve the clinical outcome in needle based prostate biopsy procedures by using AI and robotics, turning an operator-dependent procedure into a safe, accurate, and repeatable robot-assisted procedure. Needleye Robotics is bringing to the market the results of many years of research on AI-powered robotic devices for the diagnosis of prostate cancer. Our product combines the power of AI, machine learning, and robotics to help radiologists and urologists minimizing the diagnostic error and achieve a speedy and effective therapy.